A phase II study of continuous infusion 5‐fluorouracil in advanced hormone refractory prostate cancer. An illinois cancer center study

Timothy M. Kuzel*, Martin S. Tallman, Daniel Shevrin, Edward Braud, Lary Kilton, Patricia Johnson, James Kozlowski, Nicholas J. Vogelzang, Richard Blough, Al B. Benson

*Corresponding author for this work

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Background. 5‐Fluorouracil (5‐FU) has been previously associated with therapeutic benefit in hormone refractory prostate cancer. However, no previous study has administered 5‐FU as a prolonged continuous infusion, which may be the optimal schedule for this cell‐cycle specific agent. Methods. Therefore, 25 patients were treated with 5‐FU administered as a continuous intravenous infusion at a dose of 1000 mg/m2/day for 5 days every 28 days. Eligibility required disease defined by bidimensionally measurable lesions or evaluable lesions on bone scan or radiograph with elevated serum levels of prostate‐specific antigen (PSA), no severe cytopenias, and an Eastern Cooperative Oncology Group performance status less than 3. Prior chemotherapy was not allowed. Dose modifications were specified for mucositis and hematologic toxicity. Results. Eighteen of 22 patients were evaluable for response and toxicity, whereas 4 were evaluable for toxicity alone. Toxicity was significant using this dose and schedule and included episodes of sudden death (one patient), paroxysmal supraventricular tachycardia (one patient), and congestive heart failure (one patient). Other Grade 3 toxicities included stomatitis (two patients) and diarrhea (one patient). Significant myelosuppression did not occur. Objective responses were not observed, but 12 patients experienced stable disease with a median duration of 4 months. Conclusions. Infusional 5‐FU can not be recommended for the treatment of advanced hormone refractory prostate cancer.

Original languageEnglish (US)
Pages (from-to)1965-1968
Number of pages4
JournalCancer
Volume72
Issue number6
DOIs
StatePublished - Jan 1 1993

Fingerprint

Prostatic Neoplasms
Hormones
Neoplasms
Appointments and Schedules
Paroxysmal Tachycardia
Stomatitis
Mucositis
Supraventricular Tachycardia
Sudden Death
Intravenous Infusions
Diarrhea
Heart Failure
Antigens
Bone and Bones
Drug Therapy
Therapeutics
Serum

Keywords

  • 5‐fluorouracil
  • chemotherapy
  • continuous infusion
  • prostate cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Kuzel, Timothy M. ; Tallman, Martin S. ; Shevrin, Daniel ; Braud, Edward ; Kilton, Lary ; Johnson, Patricia ; Kozlowski, James ; Vogelzang, Nicholas J. ; Blough, Richard ; Benson, Al B. / A phase II study of continuous infusion 5‐fluorouracil in advanced hormone refractory prostate cancer. An illinois cancer center study. In: Cancer. 1993 ; Vol. 72, No. 6. pp. 1965-1968.
@article{c944455a305c4a2f8aa08e2da20ecf74,
title = "A phase II study of continuous infusion 5‐fluorouracil in advanced hormone refractory prostate cancer. An illinois cancer center study",
abstract = "Background. 5‐Fluorouracil (5‐FU) has been previously associated with therapeutic benefit in hormone refractory prostate cancer. However, no previous study has administered 5‐FU as a prolonged continuous infusion, which may be the optimal schedule for this cell‐cycle specific agent. Methods. Therefore, 25 patients were treated with 5‐FU administered as a continuous intravenous infusion at a dose of 1000 mg/m2/day for 5 days every 28 days. Eligibility required disease defined by bidimensionally measurable lesions or evaluable lesions on bone scan or radiograph with elevated serum levels of prostate‐specific antigen (PSA), no severe cytopenias, and an Eastern Cooperative Oncology Group performance status less than 3. Prior chemotherapy was not allowed. Dose modifications were specified for mucositis and hematologic toxicity. Results. Eighteen of 22 patients were evaluable for response and toxicity, whereas 4 were evaluable for toxicity alone. Toxicity was significant using this dose and schedule and included episodes of sudden death (one patient), paroxysmal supraventricular tachycardia (one patient), and congestive heart failure (one patient). Other Grade 3 toxicities included stomatitis (two patients) and diarrhea (one patient). Significant myelosuppression did not occur. Objective responses were not observed, but 12 patients experienced stable disease with a median duration of 4 months. Conclusions. Infusional 5‐FU can not be recommended for the treatment of advanced hormone refractory prostate cancer.",
keywords = "5‐fluorouracil, chemotherapy, continuous infusion, prostate cancer",
author = "Kuzel, {Timothy M.} and Tallman, {Martin S.} and Daniel Shevrin and Edward Braud and Lary Kilton and Patricia Johnson and James Kozlowski and Vogelzang, {Nicholas J.} and Richard Blough and Benson, {Al B.}",
year = "1993",
month = "1",
day = "1",
doi = "10.1002/1097-0142(19930915)72:6<1965::AID-CNCR2820720629>3.0.CO;2-X",
language = "English (US)",
volume = "72",
pages = "1965--1968",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "6",

}

A phase II study of continuous infusion 5‐fluorouracil in advanced hormone refractory prostate cancer. An illinois cancer center study. / Kuzel, Timothy M.; Tallman, Martin S.; Shevrin, Daniel; Braud, Edward; Kilton, Lary; Johnson, Patricia; Kozlowski, James; Vogelzang, Nicholas J.; Blough, Richard; Benson, Al B.

In: Cancer, Vol. 72, No. 6, 01.01.1993, p. 1965-1968.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A phase II study of continuous infusion 5‐fluorouracil in advanced hormone refractory prostate cancer. An illinois cancer center study

AU - Kuzel, Timothy M.

AU - Tallman, Martin S.

AU - Shevrin, Daniel

AU - Braud, Edward

AU - Kilton, Lary

AU - Johnson, Patricia

AU - Kozlowski, James

AU - Vogelzang, Nicholas J.

AU - Blough, Richard

AU - Benson, Al B.

PY - 1993/1/1

Y1 - 1993/1/1

N2 - Background. 5‐Fluorouracil (5‐FU) has been previously associated with therapeutic benefit in hormone refractory prostate cancer. However, no previous study has administered 5‐FU as a prolonged continuous infusion, which may be the optimal schedule for this cell‐cycle specific agent. Methods. Therefore, 25 patients were treated with 5‐FU administered as a continuous intravenous infusion at a dose of 1000 mg/m2/day for 5 days every 28 days. Eligibility required disease defined by bidimensionally measurable lesions or evaluable lesions on bone scan or radiograph with elevated serum levels of prostate‐specific antigen (PSA), no severe cytopenias, and an Eastern Cooperative Oncology Group performance status less than 3. Prior chemotherapy was not allowed. Dose modifications were specified for mucositis and hematologic toxicity. Results. Eighteen of 22 patients were evaluable for response and toxicity, whereas 4 were evaluable for toxicity alone. Toxicity was significant using this dose and schedule and included episodes of sudden death (one patient), paroxysmal supraventricular tachycardia (one patient), and congestive heart failure (one patient). Other Grade 3 toxicities included stomatitis (two patients) and diarrhea (one patient). Significant myelosuppression did not occur. Objective responses were not observed, but 12 patients experienced stable disease with a median duration of 4 months. Conclusions. Infusional 5‐FU can not be recommended for the treatment of advanced hormone refractory prostate cancer.

AB - Background. 5‐Fluorouracil (5‐FU) has been previously associated with therapeutic benefit in hormone refractory prostate cancer. However, no previous study has administered 5‐FU as a prolonged continuous infusion, which may be the optimal schedule for this cell‐cycle specific agent. Methods. Therefore, 25 patients were treated with 5‐FU administered as a continuous intravenous infusion at a dose of 1000 mg/m2/day for 5 days every 28 days. Eligibility required disease defined by bidimensionally measurable lesions or evaluable lesions on bone scan or radiograph with elevated serum levels of prostate‐specific antigen (PSA), no severe cytopenias, and an Eastern Cooperative Oncology Group performance status less than 3. Prior chemotherapy was not allowed. Dose modifications were specified for mucositis and hematologic toxicity. Results. Eighteen of 22 patients were evaluable for response and toxicity, whereas 4 were evaluable for toxicity alone. Toxicity was significant using this dose and schedule and included episodes of sudden death (one patient), paroxysmal supraventricular tachycardia (one patient), and congestive heart failure (one patient). Other Grade 3 toxicities included stomatitis (two patients) and diarrhea (one patient). Significant myelosuppression did not occur. Objective responses were not observed, but 12 patients experienced stable disease with a median duration of 4 months. Conclusions. Infusional 5‐FU can not be recommended for the treatment of advanced hormone refractory prostate cancer.

KW - 5‐fluorouracil

KW - chemotherapy

KW - continuous infusion

KW - prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=0027250958&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027250958&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(19930915)72:6<1965::AID-CNCR2820720629>3.0.CO;2-X

DO - 10.1002/1097-0142(19930915)72:6<1965::AID-CNCR2820720629>3.0.CO;2-X

M3 - Article

C2 - 8364875

AN - SCOPUS:0027250958

VL - 72

SP - 1965

EP - 1968

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 6

ER -